FineMark National Bank & Trust’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

FineMark National Bank & Trust’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-56	Closed	-$4K	–	420
2018 Q2	$4K	Hold	56	–	–	﹤0.01%	400
2018 Q1	$5K	Hold	56	–	–	﹤0.01%	389
2017 Q4	$42K	Hold	56	–	–	﹤0.01%	364
2017 Q3	$16K	Hold	56	–	–	﹤0.01%	369
2017 Q2	$14K	Hold	56	–	–	﹤0.01%	355
2017 Q1	$19K	Hold	56	–	–	﹤0.01%	367
2016 Q4	$34K	Hold	56	–	–	﹤0.01%	713
2016 Q3	$64K	Hold	56	–	–	0.01%	557
2016 Q2	$62K	Hold	56	–	–	0.01%	540
2016 Q1	$73K	Hold	56	–	–	0.01%	490
2015 Q4	$139K	Sell	56 -75	-57%	-$115K	0.02%	380
2015 Q3	$145K	Hold	131	–	–	0.02%	380
2015 Q2	$132K	Buy	131 +75	+134%	+$80.9K	0.02%	415
2015 Q1	$57K	Hold	56	–	–	0.01%	631
2014 Q4	$188K	Buy	56 +46	+460%	+$141K	0.03%	357
2014 Q3	$29K	Hold	10	–	–	﹤0.01%	787
2014 Q2	$37K	Hold	10	–	–	0.01%	714
2014 Q1	$54K	Sell	10 -5	-33%	-$26.3K	0.01%	591
2013 Q4	$47K	Sell	15 -15	-50%	-$46.3K	0.01%	592
2013 Q3	$97K	Sell	30 -9	-23%	-$24.5K	0.02%	430
2013 Q2	$125K	Buy	+39	New	+$125K	0.04%	353

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

FineMark National Bank & Trust's NBSE Position: Q3 2018 in Review

FineMark National Bank & Trust sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2018, closing a stake of 56 shares — an estimated $4K sold.

FineMark National Bank & Trust first reported a position in NBSE in Q2 2013 and held it in 21 quarters. The position peaked at $188K in Q4 2014. 29 funds tracked by Wall St. Rank hold NBSE as of Q3 2018.

FineMark National Bank & Trust reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
FineMark National Bank & Trust sold 56 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $4K.
FineMark National Bank & Trust first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2013 and held it in 21 quarters.
FineMark National Bank & Trust's NeuBase Therapeutics, Inc. Common Stock position peaked at $188K in Q4 2014.
29 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2018.

Based on FineMark National Bank & Trust's 13F filing for Q3 2018, filed 2 Nov 2018.